Caleb Cheng, Jing Hu, Rahul Mannan, Rupam Bhattacharyya, Nicholas J Rossiter, Brian Magnuson, Jasmine P Wisniewski, Yang Zheng, Lanbo Xiao, Chungen Li, Dominik Awad, Tongchen He, Yi Bao, Yuping Zhang, Xuhong Cao, Zhen Wang, Rohit Mehra, Pietro Morlacchi, Vaibhav Sahai, Marina Pasca di Magliano, Yatrik M Shah, Ke Ding, Yuanyuan Qiao, Costas A Lyssiotis, Arul M Chinnaiyan
Pancreatic ductal adenocarcinoma (PDAC) subsists in a nutrient-deregulated microenvironment, making it particularly susceptible to treatments that interfere with cancer metabolism 1 2 . For example, PDAC utilizes and is dependent on high levels of autophagy and other lysosomal processes 3-5 . Although targeting these pathways has shown potential in preclinical studies, progress has been hampered by the challenge of identifying and characterizing favorable targets for drug development 6 . Here, we characterize PIKfyve, a lipid kinase integral to lysosomal functioning 7 , as a novel and targetable vulnerability in PDAC...
March 20, 2024: bioRxiv